medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104380; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . High ELF4 Expression in Human Cancers is Associated with Worse Disease Outcomes and Increased Resistance to Anticancer Agents Doris Kafita1φ, Victor Daka4φ, Panji Nkhoma1φ, Mildred Zulu3, Ephraim Zulu1, Rabecca Tembo3, Zifa Ngwira3, Florence Mwaba3, Musalula Sinkala1, Sody Munsaka1 1, University of Zambia, School of Health Sciences, Department of Biomedical Sciences, P.O. Box 50110, Nationalist Road, Lusaka, Zambia 2, University of Zambia, School of Medicine, Department of Pathology and Microbiology, P.O. Box 50110, Nationalist Road, Lusaka, Zambia 3, Copperbelt University, School of Medicine, Ndola, Zambia φ, Contributed equally Correspondence
[email protected] [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.05.16.20104380; this version posted May 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Abstract The malignant phenotype of tumour cells is fuelled by changes in the expression of various transcription factors, which include some of the well-studied proteins such as p53 and Myc.